Boston, MA 07/15/2013 (wallstreetpr) – Most recently, Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has presented its first publication on LX2761 at the 73rd American Diabetes Association in Chicago. The company’s senior vice president for metabolism research, David Powell, delivered an oral presentation during the scientific sessions of the ADA meeting. The presentation explained the effects of treatment with LX2761 on blood sugar control in diabetes-affected mice. The drug, LX2761 has been designed to be acted in the gastro-intestinal tract locally in order to lower the glucose absorption by the inhibition of SGLT1, but without any important inhibition for SGLT2 present in the kidney.
Recently, Lexicon Pharmaceuticals has made an announcement that John Northcott has joined as the company’s vice president for marketing, commercial strategy and operations. Northcott brings to the company a wide range of commercial experience across a variety of therapeutic areas including pre-launch planning as well as commercialization. He was holding the commercial roles in US and Global marketing with the companies: Genentech and Roche Group for “Avastin”, having experience in a wide range of therapeutic areas which he obtained from prior commercial positions at companies including Merck and Pfizer.
During the last trading session, the stock of Lexicon Pharmaceuticals, Inc. rose by +5.53% to reach the price of $ 2.29 on a total volume of 1.22 million shares while the total average volume is 1.05 million shares. As a result, the company is tracking gains in the biotech industry. After last close, the company’s performance is standing at +3.62% for the year 2013.
Lexicon Pharmaceuticals is a company that has its focus on the discovery of breakthrough human disease treatment. The company includes many programs in its product pipeline, namely diabetes and irritable bowel syndrome that were discovered by the research team in Lexicon. This company has its proprietary gene knockout technology which helps in the identification of over 100 potential drug targets.
